Lilly Gains GLP-1 Weight-Loss Pill Approval, Adds Neuroscience Pipeline with $7.8B Centessa Deal
Eli Lilly’s FDA approval of Foundayo delivers an average 27.3-pound (12.4%) weight loss at the highest dose in ATTAIN-1 and will launch April 6 via LillyDirect at $25/month with self-pay at $149. The proposed $7.8B acquisition of Centessa Pharmaceuticals broadens Lilly’s pipeline into neuroscience and sleep disorders.
1. FDA Approval and Launch Details
In ATTAIN-1, Foundayo achieved an average weight loss of 27.3 pounds (12.4%) at the highest dose versus 2.2 pounds with placebo. The pill will ship starting April 6 via LillyDirect at $25 per month with commercial coverage and $149 for self-pay, followed by broad retail pharmacy availability.
2. Cardiovascular and Metabolic Benefits
Across the ATTAIN program, orforglipron treatment led to reductions in waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure, underscoring potential cardiovascular risk improvements alongside significant weight loss.
3. Centessa Acquisition Expands Pipeline
Eli Lilly agreed to acquire Centessa Pharmaceuticals for up to $7.8 billion in cash, gaining access to an early-stage portfolio of sleep disorder therapies and neuroscience assets currently in clinical development.
4. Strategic Impact on Growth
The Foundayo approval and Centessa deal reflect Lilly’s strategy to diversify beyond diabetes into obesity and neuroscience, aiming to expand revenue streams and capitalize on emerging markets in weight management and neurological disorders.